Showing 1361-1370 of 1555 results for "".
- New Biomarker May Help Guide Metastatic Melanoma Treatment Decisionshttps://practicaldermatology.com/news/new-biomarker-may-guide-metastatic-melanoma-treatment-decisions/2458253/Measuring levels of Bim—a protein made by cancer-fighting T cells—via a simple blood draw can help doctors predict which metastatic melanoma patients would benefit from anti-PD-1 checkpoint blockade. Such personalized medicine can help eliminate some of the trial and error ass
- Pierre Fabre and Hill Dermaceuticals Partner in Commercial Partnership for TOLAK for AKshttps://practicaldermatology.com/news/pierre-fabre-and-hill-dermaceuticals-partner-in-commercial-partnership-for-tolak-for-aks/2458258/Pierre Fabre Dermo-Cosmetique and Hill Dermaceuticals, Inc. have entered into a strategic commercial partnership for TOLAK, a patented prescription dermatologic drug, indicated for the topical treatment of actinic keratosis lesions of the face, ears, and/or scalp. Under the terms of the a
- Zeltiq Shines Spotlight on CoolAdvantage Petite Applicator at AAD Annual Meetinghttps://practicaldermatology.com/news/zeltiq-shines-spotlight-on-coolmini-applicator-at-aad-annual-meeting/2458259/ZELTIQ® Aesthetics is showcasing the CoolAdvantage Petite™ applicator at the American Academy of Dermatology Annual Meeting (AAD) in Orlando. The CoolAdvantage technology is the only non-invasive fat removal technology cleared by the Food and Drug Administration (F
- ACLARIS files NDA For Novel Seborrheic Keratosis Treatmenthttps://practicaldermatology.com/news/aclaris-files-nda-for-novel-seborrheic-keratosis-treatment/2458272/Aclaris Therapeutics, Inc. submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for A-101 40% topical solution (A-101) as a treatment for seborrheic keratosis (SK). If approved, A-101 would be the first FDA-approved t
- Galderma's OTC Differin Gel Hits Store Shelveshttps://practicaldermatology.com/news/galdermas-otc-differin-gel-hits-stores/2458299/Galderma’s Differin Gel 0.1% (adapalene) is now available over the counter (OTC) at major retail and drug stores. Galderma officially launched the gel at a New York City media fete, and the skin care co
- FDA OKs Coolsculpting for Upper Arm Fat Reductionhttps://practicaldermatology.com/news/fda-oks-coolsculpting-for-upper-arm-fat-reduction/2458300/ZELTIQ® Aesthetics, Inc.’s CoolSculpting is now US Food and Drug Administration (FDA)-cleared for fat reduction in the upper arms.
- New Compound May Block Spread of Melanoma, Treat Sclerodermahttps://practicaldermatology.com/news/new-compound-may-block-spread-of-melanoma-treat-scleroderma/2458329/A chemical compound, and potential new drug, may reduce the spread of melanoma cells by up to 90 percent, report researchers from Michigan State University in East Lansing. The man-made, small-molecule drug compound goes after a gene’s ability to produce RNA molecules and certain pr
- Carmex Rolls Out New Comfort Care Lip Balmshttps://practicaldermatology.com/news/carmex-rolls-out-new-comfort-care-lip-balms/2458343/Harsh winter weather can wreak havoc on the lips, leaving them dry, chapped and irritated. New CARMEX COMFORT CARE™ lip balms can help, says New York City dermatologist Neil Sadick, MD at a media event. Launched in late 2016, the new line is fo
- FDA Approved Eucrisa (Crisaborole) for ADhttps://practicaldermatology.com/news/fda-approved-eucrisa-crisaborole-for-ad/2458344/The U.S. Food and Drug Administration approved Eucrisa (crisaborole) ointment to treat mild-to-moderate eczema in patients two years of age and older. Eucrisa, applied topically twice daily, is a phosphodiesterase 4 (PDE-4) i
- AnaptysBio, Inc.'s IL-33-Blocker Cleared for Phase 2a Trials in AD, Peanut Allergyhttps://practicaldermatology.com/news/anaptysbio-incs-il-33-blocker-cleared-for-phase-2a-trials-in-ad-peanut-allergy/2458347/The United Kingdom Medicines and Healthcare Products Regulatory Agency has green lighted a Phase 2a clinical trial for AnaptysBio, Inc.’s ANB020 for the treatment of adults with moderate-to-severe atopic dermatitis. The United States Food and Drug Ad